AMARIN CORP PLC\UK
AMRNNasdaq
$13.94
↓ -1.7%Jul 17 close · end-of-day
Price
1Y↓ -12.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.8B
Enterprise Value
$5.5B
P/E
—
P/S
26.9
P/B
13.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$216.8M
Net Income (TTM)
-$33.6M
Free Cash Flow (TTM)
—
Gross Margin
52.4%
Operating Margin
-20.6%
Net Margin
-15.5%
ROE
-7.5%
ROIC
-25.0%
Debt / Equity
—
Net Cash
$307.8M
Return 1Y
-11.7%
Company profile
Amarin Corp. Plc is a biopharmaceutical company, which engages in the commercialization and development of therapeutics for cardiovascular health. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
- CEO
- Karim Mikhail
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 360
- Website
- www.amarincorp.com
Earnings
AMRN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$45.1M↑ +7.4%
Diluted EPS-$0.03↓ -25.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $614.1M | $583.2M | $369.2M | $306.9M | $228.6M | $213.6M |
| Gross profit | $482.6M | $461.9M | $242.5M | $165.5M | $81.4M | $120.9M |
| Operating income | -$19.7M | $10.5M | -$105.9M | -$67.6M | -$91.8M | -$50.2M |
| Net income | -$18.0M | $7.7M | -$105.8M | -$55.0M | -$87.0M | -$38.8M |
| Diluted EPS | -$0.05 | $0.02 | -$0.26 | -$0.15 | -$0.20 | -$0.09 |
| Operating cash flow | -$21.7M | -$66.5M | -$180.1M | $6.9M | -$31.0M | $6.7M |
| Free cash flow | -$22.0M | — | — | — | — | — |
| Gross margin | 78.6% | 79.2% | 65.7% | 53.9% | 35.6% | 56.6% |
| Operating margin | -3.2% | 1.8% | -28.7% | -22.0% | -40.2% | -23.5% |
| Net margin | -2.9% | 1.3% | -28.7% | -17.9% | -38.1% | -18.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $67.5M | $42.3M | $62.3M | $42.0M | $72.7M | $49.7M | $49.2M | $45.1M |
| Gross profit | $42.8M | $16.3M | -$9.6M | $25.1M | $50.4M | $22.2M | $23.2M | $17.8M |
| Operating income | -$524,000.00 | -$25.2M | -$52.5M | -$16.8M | -$16.0M | -$11.1M | -$6.3M | -$11.3M |
| Net income | $1.5M | -$25.1M | -$53.4M | -$15.7M | -$14.1M | -$7.7M | -$1.2M | -$10.5M |
| Diluted EPS | $0.00 | -$0.06 | -$0.12 | -$0.04 | -$0.03 | -$0.02 | $0.00 | -$0.03 |
| Operating cash flow | -$2.7M | -$2.4M | -$13.3M | -$12.5M | $16.6M | -$12.7M | $15.3M | $6.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 63.4% | 38.5% | -15.4% | 59.8% | 69.2% | 44.7% | 47.1% | 39.4% |
| Operating margin | -0.8% | -59.5% | -84.3% | -39.9% | -22.0% | -22.4% | -12.9% | -25.1% |
| Net margin | 2.3% | -59.4% | -85.8% | -37.4% | -19.4% | -15.6% | -2.5% | -23.3% |
Company news
Jan 11, 2024
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.